SRG OncoRat: Building a Better Trap for Cancer
SRG OncoRat, developed using Hera Biolabs’ advanced gene editing technology, is a SCID rat on the Sprague-Dawley background that harbors a double knockout for the Rag2 and Il2rgamma genes. Similar to industry leading NSG mice, OncoRat demonstrates enhanced immunodeficiency, lacking B-cells, T-cells, and NK-cells.
Combining these genetic changes in this immunodeficient rat allows the use of fewer animals through enhanced engraftment rates and improved tumor growth profiles for both cell-line tumor models and patient-derived xenografts (PDXs). OncoRat is Reliable, Efficient & Robust for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.
Delivered directly from our partners with industry-leading health standards.